No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation

Transplant Proc. 1995 Dec;27(6):3535.

Authors

H Hägglund¹, O Ringdén, P Ljungman, J Winiarski, B Ericzon, G Tydén

Affiliation

¹ Division of Transplant Surgery, Huddinge Hospital, Sweden.

PMID: 8540088

No abstract available

Publication types

Clinical Trial

MeSH terms

Adolescent
Adult
Anemia, Aplastic / therapy
Bone Marrow Transplantation / adverse effects*
Child
Child, Preschool
Female
Hemorrhage / chemically induced
Hepatic Veno-Occlusive Disease / drug therapy*
Hepatic Veno-Occlusive Disease / etiology*
Hepatic Veno-Occlusive Disease / surgery
Humans
Infant
Leukemia / therapy
Liver Transplantation
Male
Middle Aged
Recombinant Proteins / adverse effects
Retrospective Studies
Tissue Plasminogen Activator / adverse effects*
Transplantation, Homologous

Substances

Recombinant Proteins
Tissue Plasminogen Activator